Profile data is unavailable for this security.
About the company
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).
- Revenue in USD (TTM)352.75m
- Net income in USD64.59m
- Incorporated1996
- Employees112.00
- LocationInnoviva Inc1350 OLD BAYSHORE HIGHWAY, SUITE 400BURLINGAME 94010United StatesUSA
- Phone+1 (650) 238-9600
- Fax+1 (302) 655-5049
- Websitehttps://www.inva.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elite Pharmaceuticals Inc | 71.17m | -6.39m | 659.87m | 64.00 | -- | 13.96 | -- | 9.27 | -0.0059 | -0.0059 | 0.0677 | 0.0443 | 0.8957 | 2.68 | 4.46 | 1,112,051.00 | -8.04 | 19.07 | -10.06 | 24.29 | 44.73 | 46.63 | -8.98 | 20.77 | 2.42 | 0.75 | 0.1634 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
| Pliant Therapeutics Inc | 0.00 | -201.68m | 781.97m | 158.00 | -- | 2.26 | -- | -- | -3.34 | -3.34 | 0.00 | 5.68 | 0.00 | -- | -- | 0.00 | -40.90 | -33.24 | -43.90 | -35.39 | -- | -- | -- | -360.29 | -- | -- | 0.0802 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Avid Bioservices Inc | 142.36m | -144.17m | 783.46m | 371.00 | -- | 13.33 | -- | 5.50 | -2.27 | -2.27 | 2.24 | 0.9192 | 0.3661 | 3.81 | 4.32 | 383,714.30 | -37.08 | -0.826 | -57.59 | -1.20 | 6.27 | 19.26 | -101.27 | -2.14 | 1.05 | -3.18 | 0.7343 | -- | -6.27 | 21.15 | -54,444.79 | -- | 84.15 | -- |
| Pacira Biosciences Inc | 694.96m | -90.73m | 802.49m | 711.00 | -- | 1.07 | -- | 1.15 | -2.15 | -2.15 | 13.03 | 16.24 | 0.4548 | 1.71 | 7.03 | 977,436.00 | -5.94 | 3.35 | -6.83 | 3.98 | 74.35 | 72.63 | -13.06 | 8.57 | 1.89 | -- | 0.4393 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Evolus Inc | 248.33m | -55.46m | 825.71m | 322.00 | -- | 140.03 | -- | 3.33 | -0.9141 | -0.9141 | 4.11 | 0.0931 | 1.25 | 4.59 | 6.61 | 909,619.10 | -27.90 | -40.92 | -38.48 | -59.74 | 69.94 | 65.43 | -22.33 | -80.46 | 2.23 | -2.04 | 0.9537 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Liquidia Corp | 15.61m | -119.48m | 852.59m | 136.00 | -- | 7.76 | -- | 54.62 | -1.62 | -1.62 | 0.2111 | 1.31 | 0.0857 | -- | 4.14 | 114,779.40 | -65.55 | -55.02 | -75.02 | -62.69 | 64.65 | 82.18 | -765.37 | -474.59 | 6.33 | -31.14 | 0.5059 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Phibro Animal Health Corp | 1.05bn | 17.41m | 962.37m | 1.94k | 55.35 | 3.72 | 17.92 | 0.9194 | 0.4293 | 0.4293 | 25.82 | 6.38 | 1.08 | 2.60 | 6.75 | 539,568.10 | 1.80 | 3.93 | 2.20 | 4.90 | 31.47 | 31.18 | 1.66 | 3.77 | 1.69 | 2.20 | 0.6472 | 56.45 | 4.07 | 4.21 | -92.59 | -46.35 | 6.65 | 0.8548 |
| Collegium Pharmaceutical Inc | 599.25m | 88.59m | 980.73m | 197.00 | 15.21 | 4.18 | 4.14 | 1.64 | 2.00 | 2.00 | 13.05 | 7.27 | 0.4261 | 6.25 | 2.92 | 3,041,853.00 | 6.30 | 2.79 | 9.38 | 4.80 | 62.36 | 50.88 | 14.78 | 5.16 | 0.8832 | 3.94 | 0.7873 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 138.16m | -72.58m | 1.12bn | 154.00 | -- | 15.04 | -- | 8.12 | -0.7894 | -0.7894 | 1.48 | 0.775 | 0.7647 | 1.04 | 6.38 | 897,142.90 | -40.17 | -40.21 | -54.87 | -47.99 | 91.92 | -- | -52.53 | -374.75 | 2.60 | -6.11 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 555.46m | -8.77m | 1.17bn | 642.00 | -- | 2.90 | 22.76 | 2.11 | -0.4489 | -0.4489 | 28.67 | 20.44 | 0.5102 | 1.75 | 2.96 | 865,196.30 | -0.6514 | -2.83 | -0.7654 | -3.35 | 59.79 | 60.18 | -1.28 | -6.15 | 1.97 | 0.7018 | 0.5921 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Tilray Brands Inc | 812.04m | -212.62m | 1.18bn | 2.65k | -- | 0.3297 | -- | 1.46 | -0.2746 | -0.2746 | 1.03 | 3.97 | 0.1875 | 2.31 | 8.73 | 306,429.10 | -4.64 | -- | -5.15 | -- | 29.42 | -- | -24.78 | -- | 1.57 | -1.16 | 0.0953 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Innoviva Inc | 352.75m | 64.59m | 1.19bn | 112.00 | 27.71 | 1.78 | 11.42 | 3.38 | 0.6879 | 0.6879 | 4.78 | 10.68 | 0.2916 | 1.14 | 4.44 | 3,149,509.00 | 5.34 | 26.24 | 5.98 | 28.53 | 87.93 | -- | 18.31 | 76.84 | 1.64 | 1.93 | 0.4011 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Ocular Therapeutix Inc | 61.44m | -174.34m | 1.33bn | 267.00 | -- | 3.79 | -- | 21.62 | -1.30 | -1.30 | 0.4442 | 2.25 | 0.1883 | 2.48 | 2.28 | 230,116.10 | -53.42 | -46.70 | -59.98 | -54.18 | 90.59 | 89.36 | -283.75 | -228.65 | 12.94 | -27.52 | 0.1615 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Harrow Inc | 169.14m | -33.41m | 1.56bn | 315.00 | -- | 26.95 | -- | 9.21 | -0.9408 | -0.9408 | 4.76 | 1.63 | 0.5305 | 4.86 | 4.69 | 536,946.10 | -10.48 | -10.86 | -12.74 | -12.71 | 72.56 | 70.75 | -19.75 | -15.35 | 1.44 | -0.3529 | 0.7635 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Immunocore Holdings PLC - ADR | 296.55m | -47.11m | 1.61bn | 497.00 | -- | 4.25 | -- | 5.42 | -0.9494 | -0.9494 | 5.88 | 7.55 | 0.3593 | 0.541 | 5.68 | 596,681.90 | -5.71 | -27.55 | -7.45 | -36.82 | 99.38 | -- | -15.89 | -97.12 | 3.76 | -- | 0.5373 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
Data as of Nov 21 2024. Currency figures normalised to Innoviva Inc's reporting currency: US Dollar USD
74.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 8.47m | 13.54% |
| Sarissa Capital Management LPas of 30 Sep 2024 | 7.28m | 11.63% |
| Putnam Investment Management LLCas of 30 Sep 2024 | 6.68m | 10.68% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 6.12m | 9.78% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 4.50m | 7.20% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 4.33m | 6.92% |
| Pacer Advisors, Inc.as of 30 Sep 2024 | 2.81m | 4.49% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.45m | 3.92% |
| Westfield Capital Management Co. LPas of 30 Sep 2024 | 1.99m | 3.19% |
| Systematic Financial Management LPas of 30 Sep 2024 | 1.98m | 3.16% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
